Enzalutamide-induced “BRCAness” and PARP inhibition is a synthetic lethal therapy for castration-resistant prostate cancer

Cancers with dysfunctional mutations in BRCA1 or BRCA2, most commonly associated with some breast cancers, are deficient in the DNA damage repair pathway called homologous recombination (HR), which makes them exquisitely vulnerable to poly(ADP-ribose) polymerase (PARP) inhibitors, such as olaparib....

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Sci Signal
Główni autorzy: Li, Likun, Karanika, Styliani, Yang, Guang, Wang, Jiangxiang, Park, Sanghee, Broom, Bradley, Manyam, Ganiraju C., Wu, Wenhui, Luo, Yong, Basourakos, Spyridon, Song, Jian H., Gallick, Gary E., Karantanos, Theodoros, Korentzelos, Dimitrios, Azad, Abul Kalam, Kim, Jeri, Corn, Paul G., Aparicio, Ana M., Logothesis, Christopher J., Troncoso, Particia, Timothy, Heffernan, Toniatti, Carlo, Lee, Hyun-Sung, Lee, Ju-Seog, Zuo, Xuemei, Chang, Wenjun, Yin, Jianhua, Thompson, Timothy C.
Format: Artigo
Język:Inglês
Wydane: 2017
Hasła przedmiotowe:
Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5855082/
https://ncbi.nlm.nih.gov/pubmed/28536297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scisignal.aam7479
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy